ANI Pharma

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ANI Pharma posts record revenues, eyes growth in Rare Disease

ANI Pharmaceuticals delivered robust financial results, showcasing strong revenue growth and EBITDA improvement. The company's focus on Rare Disease and Generics businesses, along with strategic initiatives for 2023, positions it well for continued growth. Challenges in cash flow management and cautious information sharing require attention.

ANI Pharma reports record Q1 revenues, eyes Rare Disease M&A

ANI Pharma (ANIP) delivered strong financial performance in Q1 2023, with record revenues and raised full-year guidance, driven by successful product launches and operational efficiency.
The company's focus on sustainable growth, patient care, and strategic investments in the Rare Disease space position ANI for future success.
While facing challenges such as increased operating expenses and debt obligations, ANI's strengths in revenue growth and market reception of key products provide opportunities for continued expansion.
ANI's commitment to organic deleveraging, cash generation, and potential M&A activities underscore a strategic approach to long-term growth and financial stability.

ANI Pharma reports stellar Q2 results, eyes rare disease expansion

ANI Pharma delivered exceptional financial performance in Q2 2023, driven by strong revenue growth and record EBITDA.
The company's focus on rare diseases and generics, along with a solid financial position, positions it well for future growth.
ANI Pharma faces challenges in maintaining growth momentum and navigating industry competition but has opportunities for expansion.

ANI Pharma reports record Q3 revenues, raises full-year guidance

ANI Pharmaceuticals (ANIP) delivered impressive Q3 results with record revenues and substantial growth in key segments. Despite market challenges, the company's strategic investments and raised guidance signal confidence in future performance and expansion.

ANI Pharmaceuticals reports record 2023 earnings, eyes growth opportunities

ANI Pharmaceuticals delivered a stellar performance in Q4 2023, achieving record revenue and profitability figures, driven by strong sales in key product segments.
While the company faces challenges in maintaining growth rates and navigating market dynamics, ANI Pharmaceuticals is well-positioned to capitalize on opportunities for expansion and innovation.
With a solid financial foundation, diverse product portfolio, and strategic growth outlook for 2024, ANI Pharmaceuticals remains poised for continued success and market leadership in the pharmaceutical industry.

ANI Pharma reports strong Q1 earnings, eyes Rare Disease growth

ANI Pharma's Q1 2024 performance reflects robust revenue growth across key segments, supported by strategic initiatives and a focus on innovation.
While facing challenges in R&D spending variability and supply tailwinds, the company remains well-positioned to capitalize on growth opportunities.
Opportunities lie in expanding the Rare Disease business, exploring new specialties for Cortrophin Gel, and pursuing strategic M&A for sustained growth.
ANI Pharma's prudent approach to capital deployment and confidence in growth through acquisitions underscore a promising outlook for future expansion.

ANI Pharma reports record revenues, announces Alimera acquisition for growth

ANI Pharma delivered a strong Q2 2024 performance with record revenues and significant growth in key product segments.
The proposed acquisition of Alimera Sciences signals ANI's strategic expansion into high-growth commercial products, enhancing its market position.
While facing integration challenges, ANI's raised guidance and focus on accretive EPS from the acquisition highlight a positive outlook for future growth.

ANI Pharmaceuticals (ANIP) reports record Q3 revenues and eyes rare disease growth in 2025

ANI Pharmaceuticals (ANIP) delivered a robust Q3 performance with record revenues and raised full-year guidance, driven by strong growth in Cortrophin Gel and generics business. The company's emphasis on rare diseases and new offerings positions it for continued growth in 2025. While challenges exist in the payer landscape and acquisition integration, ANIP's strategic focus on key specialties offers promising opportunities for expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference 2021 as follows: Date: Friday, June 4, 2021 Time: 10:00 a.m. ET Webcast Link: https://wsw.com/webcast/jeff174/anip/1843128 The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the

ANI Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021

ANI Pharmaceuticals posted much better quarterly results than expected on Friday. This triggered a 15% rally in the stock that day, which the shares promptly gave back in yesterday's market sell-off.

Post Earnings Assessment On ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani on Q1 2021 Results - Earnings Call Transcript

ANI (ANIP) delivered earnings and revenue surprises of 42.47% and 13.59%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Q1 Earnings and Revenues Top Estimates

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three months ended March 31, 2021. First Quarter and Recent Business Highlights: Continued efforts to assemble a robust re-filing package for Cortrophin® Gel in preparation for second-quarter 2021 submission to the U.S. Food and Drug Administration (“FDA”). Signed a definitive agreement to acquire Novitium Pharma LLC (“Novitium”),

ANI Pharmaceuticals Reports First Quarter 2021 Results

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: ANI Pharmaceuticals (ANIP) Q1 Earnings Expected to Decline

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2021 financial results on Friday, May 7, 2021. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date Friday, May 7, 2021 Time 8:30 a.m. ET Toll free (U.S.) 866-518-6930 Webcast (live

ANI Pharmaceuticals to Discuss First Quarter 2021 Financial Results on May 7, 2021

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI”) (NASDAQ:ANIP) today announced that it has acquired the new drug applications (“NDAs”) for OXISTAT® Lotion, VEREGEN® Ointment, and Pandel® Cream and the abbreviated new drug application (“ANDA”) for ApexiCon® E Cream from Sandoz Inc. Pandel® Cream will be transitioned later upon receiving the requisite approvals. Collectively, these products generated net revenues of $13.2 million in 2020. The acquisition was funded through borr

ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs

ANI Pharmaceuticals (ANIP) has moved higher as of late, but there could definitely be trouble on the horizon for this company

ANI Pharmaceuticals (ANIP) Enters Overbought Territory

ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani on Q4 2020 Results - Earnings Call Transcript

ANI (ANIP) delivered earnings and revenue surprises of -20.00% and 3.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Q4 Earnings Miss Estimates

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and 12 months ended December 31, 2020. Corporate Strategy The Company's strategy for sustainable future growth is based on four key pillars: Build a successful Cortrophin franchise; Strengthen the Generics business by enhancing development capabilities and increased focus on niche opportunities. The acquisition of Novitium Ph

ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results; Company Positioned for Sustainable Future Growth

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities for $163.5 million, including $89.5 million in cash and $74 million in equity plus two potential future cash earn-outs of up to $46.5 million. The transaction has been approved by the ANI

ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business

ANI Pharmaceuticals (NASDAQ:ANIP) announces its next round of earnings this Tuesday, March 09. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement.

ANI Pharmaceuticals's Earnings: A Preview

Earnings Preview: ANI Pharmaceuticals (ANIP) Q4 Earnings Expected to Decline

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI“ or the “Company“) (Nasdaq: ANIP) today announced that ANI's Board of Directors granted non-qualified inducement stock options to purchase an aggregate of 27,006 shares of ANI's common stock to Ori Gutwerg, ANI's Senior Vice President, Generics, and an aggregate of 33,758 shares to Christopher Mutz, ANI's Chief Commercial Officer & Head of Rare Disease, effective February 15, 2021. The stock options were granted as inducement

ANI Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the addition of three key pharmaceutical executives: Christopher K. Mutz as Chief Commercial Officer and Head of Rare Diseases; Ori Gutwerg as Senior Vice President of Generics; and Davinder Singh as General Manager, Canadian Operations. “We are delighted to welcome Chris, Ori and Davinder to ANI. Their collective experience and individual areas of expertise strengthen our team to

ANI Pharmaceuticals Strengthens Leadership Team to Accelerate Future Growth

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2020 financial results on Tuesday, March 9, 2021. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date Tuesday, March 9, 2021 Time 8:30 a.m. ET Toll free (U.S.) (866)

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prazosin HCl Capsules USP, 1mg and 2mg, following the U.S. Food and Drug Administration's (“FDA”) approval of the Company's prior approval supplement application (“PAS”). The current annual U.S. market for Prazosin 1mg and 2mg strengths is approximately $46.2 million, according to IQVIA/IMS Health. "Launch of Prazosin HCl is ANI's fourteenth re-commercialization of a

ANI Pharmaceuticals Announces Launch of Prazosin Hydrochloride (“HCl”) Capsules

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval and the launch of Aminocaproic Acid Tablets USP, 500mg. The current annual U.S. market for this product is approximately $12.7 million, according to IQVIA/IMS Health. "This is ANI's seventh generic product launch in 2020 and reaffirms our commitment to increasing the pace of market introductions for our products. This important ther

ANI Pharmaceuticals Announces Approval and Launch of Aminocaproic Acid Tablets

Let's see if ANI Pharmaceuticals (ANIP) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Pick ANI Pharmaceuticals (ANIP) Now?

ANI Pharmaceuticals, Inc.'s (ANIP) CEO Nikhil Lalwani on Q3 2020 Results - Earnings Call Transcript

Surgalign Holdings, Inc.

Vanda Pharmaceuticals

PetMed Express

Surmodics

According to the GuruFocus All-in-One Screener as of Nov. 5, the following medical technology stocks are popular among gurus.

5 Medical Technology Stocks Popular Among Gurus

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and nine months ended September 30, 2020. Business and Recent Highlights: Company's supplemental New Drug Application (“sNDA”) for lead product, Cortrophin Gel, re-filing on track; driving commercial and operational readiness for a successful launch; Welcomed Nikhil Lalwani as President and CEO, on September 8, 2020; and Broa

ANI Pharmaceuticals Reports Third Quarter 2020 Results

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2020 financial results on Thursday, November 5, 2020, before the opening of the U.S. financial markets. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date Thursday, November 5, 2020 Time

News for ANI Pharma Stock (ANIP)